Summary
Hims & Hers, a healthcare company, announced a partnership with GRAIL to offer their customers the Galleri multi-cancer detection test at a discount. This comes as President Donald Trump signed a new law to support Medicare coverage of these tests once they get FDA approval. The Galleri test aims to detect signals for over 50 types of cancer from a blood sample.
Key Facts
- Hims & Hers is partnering with GRAIL to offer a cancer detection test to their customers.
- The Galleri test can detect signals for more than 50 different types of cancer through a blood sample.
- President Trump signed a law to pave the way for Medicare to cover multi-cancer detection tests after they receive FDA approval.
- The Galleri test has not yet received approval from the FDA.
- Some doctors worry that patients might skip recommended screenings if they receive a negative test result.
- Costs of these cancer detection tests might limit access for some patients.
- Official guidelines and Medicare decisions influence whether insurers will pay for these tests.
